Therma Bright Inc., a developer and investment partner in advanced diagnostic and medical device technologies, has announced the addition of Steve Raysely to its Advisory Board. With over two decades of experience in healthcare and technology sales, marketing, and operations, Mr. Raysely brings valuable expertise to the Company. He will provide strategic counsel on product market positioning, commercial expansion, and the deployment of emerging health technologies.
In addition to this announcement, Therma Bright has negotiated debt settlements with creditors. The Company proposes to settle aggregate debt of $168,300 by issuing 3,366,000 common shares at a deemed price of $0.05 per share. This settlement is subject to acceptance by the TSX Venture Exchange. Furthermore, the Company has issued an aggregate of 2,825,000 common shares at a deemed price of $0.04 per share to settle aggregate debt of $113,000. All shares issued in relation to this settlement are subject to a hold period expiring on May 4, 2025.
Therma Bright Inc. is focused on providing consumers and medical professionals with innovative solutions to address medical and healthcare challenges. The Company trades on the TSX Venture Exchange and has a range of proprietary diagnostic and medical device technologies.
For more information about Therma Bright Inc. and its developments, visit www.thermabright.com. The Company’s forward-looking statements involve known and unknown risks and uncertainties, and it cannot guarantee that actual results will be consistent with these statements. The TSX Venture Exchange does not endorse or verify the accuracy of this press release.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
